Clinical Trials Logo

Filter by:
NCT ID: NCT04697160 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL

RE-MIND2
Start date: April 1, 2020
Phase:
Study type: Observational

To compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCN/ESMO guideline listed regimens administered in routine clinical care.

NCT ID: NCT04696367 Completed - Surgery Clinical Trials

Impact of Nutritional Deficit in Emergency Surgery

INDIcatES
Start date: January 1, 2020
Phase:
Study type: Observational

Patients in emergency settings might become malnourished. There are different ways to identify the group as 'at risk' of malnutrition. There are also several different ways to measure outcomes. This pilot study will look at patients undergoing emergency laparotomy, investigate relationships between different selection criteria and outcome measures, and test feasibility of outcome measure collection.

NCT ID: NCT04695431 Completed - Mast Cell Leukemia Clinical Trials

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Start date: December 2, 2020
Phase:
Study type: Observational

BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.

NCT ID: NCT04695041 Completed - Inflammation Clinical Trials

A Healthy Volunteer Study of PBI-4050

Start date: December 9, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the study drug PBI-4050 to determine the safety, tolerability and concentration profile in the blood when the drug is given to healthy volunteers as multiple doses and different dosing regimens over a period of 14 days.

NCT ID: NCT04691115 Completed - Safety Clinical Trials

Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects

Start date: December 16, 2020
Phase: Phase 1
Study type: Interventional

This is a First in Human (FIH), double-blind, randomised, placebo-controlled study designed to evaluate safety, tolerability and PK of single and multiple ascending oral doses of AM1476 in healthy subjects.

NCT ID: NCT04690335 Completed - RSV Infection Clinical Trials

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine

Start date: December 29, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate whether the investigational, live attenuated, intranasally delivered vaccine MV-012-968 ('study vaccine') may have prophylactic efficacy against symptomatic RSV infection when administered to adults 18-45 years of age in the Human Viral Challenge model.

NCT ID: NCT04688775 Completed - Clinical trials for Cluster Headache, Episodic

Eptinezumab in Participants With Episodic Cluster Headache

ALLEVIATE
Start date: December 23, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)

NCT ID: NCT04687072 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

ADVANCE SC
Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.

NCT ID: NCT04686669 Completed - Clinical trials for Relative Bioavailability

A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations

Start date: December 10, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the single-dose pharmacokinetics of FOR-6219 in capsule and tablet formulations in postmenopausal women. The effect of high-fat food on the pharmacokinetics of the tablet formulation will also be evaluated. A total of twelve, post-menopausal women, will be randomised to receive a single oral dose of FOR-6219 in three treatment periods: capsule formulation (fasted); tablet formulation (fed); tablet formulation (fasted)

NCT ID: NCT04686591 Completed - Clinical trials for Cardiovascular Disease

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

Start date: December 21, 2020
Phase: Phase 1
Study type: Interventional

Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration